BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.77% | 76.40% | 67.30% | 46.25% | -3,102.52% |
| Total Depreciation and Amortization | 601.97% | 451.32% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.73% | -35,728.53% | -3,524.16% | -311.38% | 23.76% |
| Change in Net Operating Assets | 221.63% | 299.70% | 31.07% | -5,312.08% | -2,087.77% |
| Cash from Operations | 15.58% | -1.61% | -91.99% | -99.81% | -95.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 309.32% | 10.43% | 249,900.00% | 189.53% | -38.53% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 309.32% | 11.75% | 2,046.47% | 244.31% | 205.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.01% | -3.02% | -66.50% | -88.21% | -31.98% |
